NDAORALTABLET
Approved
Oct 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENESE-R is a fixed-dose combination oral tablet containing polythiazide (a thiazide diuretic) and reserpine (an antihypertensive alkaloid) approved in 1963. It was indicated for hypertension management, leveraging dual mechanisms to reduce blood pressure through diuresis and sympathetic inhibition. This product represents a legacy small-molecule antihypertensive from the mid-20th century era.
LOE Approaching
Product is nearing loss of exclusivity with minimal competitive pressure at 30%, indicating a contracting commercial opportunity and likely reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENESE-R offers limited career advancement given its LOE-approaching status and minimal commercial opportunity. Roles on this product are typically in portfolio maintenance, legacy brand management, or regulatory compliance—not high-visibility growth assignments.
Brand Manager (legacy portfolio)Field Sales Representative
Worked on RENESE-R at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.